• Je něco špatně v tomto záznamu ?

Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC

O. Fiala, M. Pesek, J. Finek, M. Minarik, L. Benesova, O. Sorejs, M. Svaton, Z. Bortlicek, R. Kucera, O. Topolcan,

. 2016 ; 36 (1) : 455-60.

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16020058

BACKGROUND: Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) represent novel, effective tools in the management of advanced-stage non-small cell lung cancer (NSCLC). We aimed to evaluate the incidence and predictive role of EGFR gene amplification in patients with advanced-stage NSCLC treated with EGFR-TKIs. PATIENTS AND METHODS: The study included 290 patients with advanced-stage (IIIB or IV) NSCLC. Multiplex ligation-dependent probe amplification (MLPA) and polymerase chain reaction (PCR) were used for detection of EGFR gene amplification and EGFR mutations, respectively. RESULTS: EGFR amplification was detected in 26 (9.0%) patients. EGFR amplification was found more frequently in patients harboring the EGFR mutation (p<0.001). No significant corelation between EGFR gene amplification and survival was observed. CONCLUSION: EGFR gene amplification is associated with EGFR gene mutation. EGFR gene amplification is not a feasible predictive biomarker for treatment with EGFR-TKIs in patients with advanced-stage NSCLC.

000      
00000naa a2200000 a 4500
001      
bmc16020058
003      
CZ-PrNML
005      
20180511123110.0
007      
ta
008      
160722s2016 gr f 000 0|eng||
009      
AR
035    __
$a (PubMed)26722081
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Fiala, Ondřej $u Department of Oncology and Radiotherapy, Medical School and Teaching Hospital Pilsen, Charles University in Prague, Prague, Czech Republic Biomedical Center, Faculty of Medicine in Pilsen, Faculty of Sciences, Charles University in Prague, Prague, Czech Republic fiala.o@centrum.cz. $7 xx0209889
245    10
$a Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC / $c O. Fiala, M. Pesek, J. Finek, M. Minarik, L. Benesova, O. Sorejs, M. Svaton, Z. Bortlicek, R. Kucera, O. Topolcan,
520    9_
$a BACKGROUND: Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) represent novel, effective tools in the management of advanced-stage non-small cell lung cancer (NSCLC). We aimed to evaluate the incidence and predictive role of EGFR gene amplification in patients with advanced-stage NSCLC treated with EGFR-TKIs. PATIENTS AND METHODS: The study included 290 patients with advanced-stage (IIIB or IV) NSCLC. Multiplex ligation-dependent probe amplification (MLPA) and polymerase chain reaction (PCR) were used for detection of EGFR gene amplification and EGFR mutations, respectively. RESULTS: EGFR amplification was detected in 26 (9.0%) patients. EGFR amplification was found more frequently in patients harboring the EGFR mutation (p<0.001). No significant corelation between EGFR gene amplification and survival was observed. CONCLUSION: EGFR gene amplification is associated with EGFR gene mutation. EGFR gene amplification is not a feasible predictive biomarker for treatment with EGFR-TKIs in patients with advanced-stage NSCLC.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antitumorózní látky $x farmakologie $7 D000970
650    _2
$a nemalobuněčný karcinom plic $x farmakoterapie $x genetika $7 D002289
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a amplifikace genu $x genetika $7 D005784
650    _2
$a lidé $7 D006801
650    _2
$a nádory plic $x farmakoterapie $x genetika $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a erbB receptory $x genetika $7 D066246
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pesek, Milos $u Department of Pneumology, Medical School and Teaching Hospital Pilsen, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Finek, Jindrich $u Department of Oncology and Radiotherapy, Medical School and Teaching Hospital Pilsen, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Minarik, Marek $u Center for Applied Genomics of Solid Tumours, Genomac Research Institute, Prague, Czech Republic Department of Analytical Chemistry, Faculty of Sciences, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Benesova, Lucie $u Center for Applied Genomics of Solid Tumours, Genomac Research Institute, Prague, Czech Republic.
700    1_
$a Sorejs, Ondrej $u Department of Oncology and Radiotherapy, Medical School and Teaching Hospital Pilsen, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Svatoň, Martin $u Department of Pneumology, Medical School and Teaching Hospital Pilsen, Charles University in Prague, Prague, Czech Republic. $7 xx0224192
700    1_
$a Bortlicek, Zbynek $u Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Kucera, Radek $u Department of Nuclear Medicine, Medical School and Teaching Hospital Pilsen, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Topolcan, Ondrej $u Department of Nuclear Medicine, Medical School and Teaching Hospital Pilsen, Charles University in Prague, Prague, Czech Republic.
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 36, č. 1 (2016), s. 455-60
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26722081 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20180511123242 $b ABA008
999    __
$a ok $b bmc $g 1154728 $s 944586
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 36 $c 1 $d 455-60 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20160722

Najít záznam

Citační ukazatele

Možnosti archivace